Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

M&A MedTech

BD Acquires Tepha to Boost its Surgical Mesh Portfolio

Shots: The acquisition will utilize Tepha’s resorbable polymer technology to boost the growth of BD’s surgical mesh portfolio for the repair and regeneration of soft tissues The acquisition also provides strategic vertical integration for BD’s Phasix mesh products & includes Tepha’s GalaFLEX portfolio which is based on the novel P4HB polymer Additionally, an interventional segment […]Read More

Biotech

Arena and Aristea Collaborate to Develop RIST4721 for Treatment of

Shots: Aristea to receive $60M as up front and $10M as equity investment in Aristea’s Series B financing. Arena gets an exclusive option to acquire Aristea, including rights to all CXCR2 programs, post completion of the P-IIb study of RIST4721 in PPP The companies can jointly explore the development of additional neutrophil-mediated diseases, including HS […]Read More

Regulatory

Sanofi’s Avalglucosidase alfa Receives CHMP’s Positive Opinion for Patients with

Shots: The CHMP’s positive opinion is based on P-III COMET study assessing avalglucosidase alfa that demonstrated improvements in respiratory function & movement endurance measures in people with late-onset Pompe disease The CHMP concluded that avalglucosidase alfa does not qualify as a New Active Substance (NAS). Sanofi will be requesting a re-examination of the CHMP’s opinion […]Read More